Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807377 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01807377 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 15 participants.
The verdict
NCT01807377, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.
Interventions
- OTHER Placebo
- DRUG Midazolam
- DRUG PF-05175157
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-04 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807377
The ClinicalTrials.gov registry entry for NCT01807377 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01807377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01807377 about?
NCT01807377 is a clinical study titled "Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects". This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.
What is the current status of trial NCT01807377?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-04. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01807377?
The interventions under investigation include: Placebo (OTHER), Midazolam (DRUG), PF-05175157 (DRUG).
Who is sponsoring clinical trial NCT01807377?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.